All In Biotech

Drug Trial Radar · NCT07266831

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV-1

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

570

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

Feb 1, 2029

Study completion Dec 18, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.

Conditions

  • Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Interventions

  • ISLDrug

    ISL 2 x 1 mg oral capsules administered qw for 96 weeks

  • ULODrug

    ULO 2 x 100 mg oral tablets administered qw for 96 weeks

  • BIC/FTC/TAFDrug

    BIC/FTC/TAF 50/200/25 mg oral tablet administered qd for 96 weeks

  • Placebo for BIC/FTC/TAFDrug

    BIC/FTC/TAF-matching placebo oral tablet administered qd for 96 weeks

  • Placebo to ISL/ULODrug

    ISL/ULO-matching placebo oral tablets administered qw for 96 weeks

  • ISL/ULODrug

    ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL at Week 24Time frame: Week 24
  2. Phase 2: Percentage of Participants Who Experience an Adverse Event (AE) at Week 24Time frame: Week 24
  3. Phase 2: Percentage of Participants Who Discontinue Study Intervention Due to an AE at Week 24Time frame: Week 24
  4. Phase 3: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48Time frame: Week 48
  5. Phase 3: Percentage of Participants Who Experience an AE at Week 48Time frame: Week 48
  6. Phase 3: Percentage of Participants Who Discontinue Study Intervention Due to an AE at Week 48Time frame: Week 48

Locations

56 sites in 9 countries. Site status is shown where the registry gives one.

  • Ruane Clinical Research Group, Inc. ( Site 1513)

    Los Angeles, California · Recruiting

  • Vivent Health ( Site 1519)

    Denver, Colorado · Recruiting

  • Whitman-Walker Institute ( Site 1538)

    Washington D.C., District of Columbia · Recruiting

  • Midway Immunology and Research Center ( Site 1503)

    Ft. Pierce, Florida · Recruiting

  • CAN Community Health- Miami Gardens ( Site 1549)

    Miami Gardens, Florida · Recruiting

  • Orlando Immunology Center ( Site 1501)

    Orlando, Florida · Recruiting

  • CAN Community Health ( Site 1510)

    Sarasota, Florida · Recruiting

  • Triple O Research Institute ( Site 1505)

    West Palm Beach, Florida · Recruiting

  • Metro Infectious Diseases Consultants L.L.C. ( Site 1509)

    Decatur, Georgia · Recruiting

  • Mercer university, Department of internal medicine-Clinical Research ( Site 1512)

    Macon, Georgia · Recruiting

  • Rush University Medical Center-Infectious Disease ( Site 1522)

    Chicago, Illinois · Recruiting

  • Henry Ford Hospital ( Site 1535)

    Detroit, Michigan · Recruiting

  • KC CARE Health Center ( Site 1506)

    Kansas City, Missouri · Recruiting

  • ID Care ( Site 1507)

    Hillsborough, New Jersey · Recruiting

  • Atrium Health Infectious Disease Kenilworth - Charlotte ( Site 1533)

    Charlotte, North Carolina · Recruiting

  • Regional Center for Infectious Diseases ( Site 1516)

    Greensboro, North Carolina · Recruiting

  • The Ohio State University ( Site 1536)

    Columbus, Ohio · Recruiting

  • University of Pennsylvania Perelman School of Medicine ( Site 1508)

    Philadelphia, Pennsylvania · Recruiting

  • Saint Hope Foundation, Inc. ( Site 1504)

    Bellaire, Texas · Recruiting

  • Prism Health North Texas, Oak Cliff Health Center ( Site 1514)

    Dallas, Texas · Recruiting

  • North Texas Infectious Diseases Consultants ( Site 1500)

    Dallas, Texas · Active not recruiting

  • Texas Center for Infectious Disease Associates ( Site 1502)

    Fort Worth, Texas · Recruiting

  • DCOL Center for Clinical Research ( Site 1511)

    Longview, Texas · Recruiting

  • Harborview Medical Center ( Site 1526)

    Seattle, Washington · Recruiting

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 3102)

    Caba, Buenos Aires, Argentina · Recruiting

  • Fundación Huesped ( Site 3100)

    CABA, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 3103)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Fundación IDEAA ( Site 3101)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Instituto CAICI SRL ( Site 3106)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 3105)

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • Spectrum Health ( Site 3307)

    Vancouver, British Columbia, Canada · Completed

  • Gestion clinique médicale l'Actuel ( Site 3303)

    Montreal, Quebec, Canada · Recruiting

  • Biomedica Research Group ( Site 4201)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Clínica Universidad de Los Andes ( Site 4207)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Espacio Eme ( Site 4202)

    Santiago, Region M. de Santiago, Chile · Active not recruiting

  • Bordeaux University Hospital - Pellegrin ( Site 3605)

    Bordeaux, Gironde, France · Recruiting

  • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan ( Site 3608)

    Toulouse, Haute-Garonne, France · Recruiting

  • Hôpital Avicenne ( Site 3602)

    Bobigny, Île-de-France Region, France · Recruiting

  • Hôpital Saint-Louis ( Site 3600)

    Paris, Île-de-France Region, France · Recruiting

  • Hôpital Bichat - Claude-Bernard ( Site 3601)

    Paris, Île-de-France Region, France · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.